Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Decline in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totalling 76,800 shares, a decrease of 20.7% from the September 30th total of 96,900 shares. Based on an average daily volume of 1,069,300 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Trading Down 2.0 %

Shares of Bayer Aktiengesellschaft stock opened at $6.95 on Wednesday. The business has a fifty day simple moving average of $7.68 and a 200-day simple moving average of $7.48. Bayer Aktiengesellschaft has a fifty-two week low of $6.82 and a fifty-two week high of $11.34. The firm has a market cap of $27.31 billion, a price-to-earnings ratio of -7.99 and a beta of 1.08. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. The company had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.74% and a positive return on equity of 16.96%. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.